Joanna J Arch1,2, Sarah R Genung3, Michelle C Ferris3, Alex Kirk3, Elizabeth T Slivjak3, Joel N Fishbein3, Rebecca L Schneider3, Annette L Stanton4,5. 1. Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, 80309-0345, USA. Joanna.Arch@Colorado.edu. 2. Division of Cancer Prevention and Control, University of Colorado Cancer Center, Aurora, CO, 80045, USA. Joanna.Arch@Colorado.edu. 3. Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, 80309-0345, USA. 4. Department of Psychology, University of California Los Angeles, Los Angeles, CA, 90095, USA. 5. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Abstract
PURPOSE: Despite cancer survivors' frequent endorsement of anxiety symptoms, assessing the full range of anxiety disorders (AD), their timing of onset relative to cancer diagnosis, co-morbidity with mood disorder, and predictors of post-cancer onset, is rare or absent to date. This study provides a step toward addressing these gaps. METHODS: Cancer survivors at re-entry after primary treatment completion who screened positively for anxiety symptoms (N = 133) and sought care through an intervention trial completed standardized diagnostic interviews, dimensional assessment of disorder severity, and timing of disorder onset relative to cancer diagnosis. We evaluated sociodemographic and medical predictors of developing a first AD after cancer diagnosis. RESULTS: Most ADs began after cancer diagnosis (58%); for 68% of affected patients, this represented their first AD episode. The most common was generalized anxiety disorder (GAD; 41%), where "cancer-focused GAD" was distinguished from "typical GAD"; the next most common were specific phobia (14%) and social anxiety disorder (13%). A minority (31%) of ADs were comorbid with major depression. Relative to having no AD, experiencing more lingering treatment side effects predicted developing a first AD after cancer diagnosis. Relative to having an AD that began before cancer diagnosis, reporting a higher cancer stage predicted developing a first AD after diagnosis. CONCLUSIONS: Cancer survivors at re-entry seeking care for anxiety symptoms manifested a broad range of ADs which most commonly developed after cancer diagnosis and were prompted by the experience of cancer. Such disorders represent an unusually late-life, cancer-linked etiology that warrants further investigation and clinical attention.
PURPOSE: Despite cancer survivors' frequent endorsement of anxiety symptoms, assessing the full range of anxiety disorders (AD), their timing of onset relative to cancer diagnosis, co-morbidity with mood disorder, and predictors of post-cancer onset, is rare or absent to date. This study provides a step toward addressing these gaps. METHODS:Cancer survivors at re-entry after primary treatment completion who screened positively for anxiety symptoms (N = 133) and sought care through an intervention trial completed standardized diagnostic interviews, dimensional assessment of disorder severity, and timing of disorder onset relative to cancer diagnosis. We evaluated sociodemographic and medical predictors of developing a first AD after cancer diagnosis. RESULTS: Most ADs began after cancer diagnosis (58%); for 68% of affected patients, this represented their first AD episode. The most common was generalized anxiety disorder (GAD; 41%), where "cancer-focused GAD" was distinguished from "typical GAD"; the next most common were specific phobia (14%) and social anxiety disorder (13%). A minority (31%) of ADs were comorbid with major depression. Relative to having no AD, experiencing more lingering treatment side effects predicted developing a first AD after cancer diagnosis. Relative to having an AD that began before cancer diagnosis, reporting a higher cancer stage predicted developing a first AD after diagnosis. CONCLUSIONS:Cancer survivors at re-entry seeking care for anxiety symptoms manifested a broad range of ADs which most commonly developed after cancer diagnosis and were prompted by the experience of cancer. Such disorders represent an unusually late-life, cancer-linked etiology that warrants further investigation and clinical attention.
Authors: Siân E Harrison; Eila K Watson; Alison M Ward; Nada F Khan; Daniel Turner; Eike Adams; David Forman; Monica F Roche; Peter W Rose Journal: J Clin Oncol Date: 2011-04-25 Impact factor: 44.544
Authors: Peter Roy-Byrne; Michelle G Craske; Greer Sullivan; Raphael D Rose; Mark J Edlund; Ariel J Lang; Alexander Bystritsky; Stacy Shaw Welch; Denise A Chavira; Daniela Golinelli; Laura Campbell-Sills; Cathy D Sherbourne; Murray B Stein Journal: JAMA Date: 2010-05-19 Impact factor: 56.272
Authors: Joseph A Greer; Jessica M Solis; Jennifer S Temel; Inga T Lennes; Holly G Prigerson; Paul K Maciejewski; William F Pirl Journal: Psychosomatics Date: 2011 Sep-Oct Impact factor: 2.386
Authors: Michelle G Craske; Murray B Stein; Greer Sullivan; Cathy Sherbourne; Alexander Bystritsky; Raphael D Rose; Ariel J Lang; Stacy Welch; Laura Campbell-Sills; Daniela Golinelli; Peter Roy-Byrne Journal: Arch Gen Psychiatry Date: 2011-04